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Abstract 
Problem: Individuals with substance use disorder (SUD) have disproportionately higher rates of 
unintended pregnancy when compared to the general population, estimated to be 85% (Heil et 
al., 2011). Not only are poor maternal and fetal outcomes associated with unplanned pregnancies, 
but pregnancies in women with SUD are further complicated by additional risks and adverse 
outcomes (Black & Day, 2016).  
Context: Addiction treatment centers and programs are primed with opportunity to offer family 
planning services, when contact with medical providers is increased for substance use treatment. 
In response to the opioid crisis and unprecedented rates of unintended pregnancy, this project 
was designed to identify, develop, and implement an evidence-based approach to integrate birth 
control education and services, emphasizing long-acting reversible contraception (LARC) in 
substance use treatment.  
Interventions: A two-part interdisciplinary training was designed to include best practice 
recommendations regarding LARC utilization and comprehensive contraceptive counseling, 
hands-on skills training with vaginal simulators, and subdermal implant training and 
certification. In addition, a site feasibility analysis was conducted, to include a client focus 
group, staff readiness for change survey, and site assessment, to develop and make 
recommendations for a future pilot program for offering birth control services in the on-site 
medical clinic.  
Measures: A pre/post training assessment was utilized to assess change in provider confidence 
and readiness in offering contraceptive counseling and performing LARC procedures in 
preparation for service integration on site.  
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Results: Through data analysis, results indicated a 33.33% increase in provider comfort with 
providing contraceptive counseling, confidence in identifying LARC eligible candidates, and 
confidence in counseling clients about the LARC insertion procedure and follow-up. The greatest 
changes were seen in provider preparedness in providing counseling regarding LARC safety and 
efficacy, with a 44.44% increase and a 57.89% increase in provider comfortability with the 
Nexplanon insertion and removal procedure from the pre-training assessments.  
Conclusions: Didactic and hands-on training are effective approaches to prepare providers for 
service expansion to include contraceptive services at addiction treatment centers. For future 
implementation, funding through grants or expanded billing for medical services need to occur.   
Keywords: Unintended pregnancy, LARC, contraceptive counseling, substance use 
disorder, IUD, intrauterine device, birth control 
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Section II: Introduction 
Background and Problem Description 
Unintended pregnancy is a pervasive, preventable problem throughout the United States. 
Some of the highest rates of unplanned pregnancy have been identified in women with a 
substance use disorder (SUD). Both SUD and unplanned pregnancies are associated with their 
respective individual health challenges and sequelae that are further impacted when combined. 
This Doctor of Nursing Practice (DNP) project was designed to address and reduce barriers to 
family planning services among women of reproductive age with a SUD. Substance abuse and 
the geographical setting will be further discussed to provide a greater understanding of the target 
population and existing healthcare disparities. 
Substance abuse is defined as “the harmful or hazardous use of psychoactive substances, 
including alcohol and illicit drugs” (World Health Organization, 2019, para. 1). Substance abuse 
has become a widespread problem, in part due to the opioid crisis. The over prescription of 
opioids led to astonishing rates of misuse (21% to 29%) and the development of opioid use 
disorder (8% to 12%) in the population (National Institute on Drug Abuse [NIDA], 2019). 
Despite the increasing demand for substance abuse treatment, less than 1% are able to receive 
treatment (NIDA, 2015). Peak drug usage occurs in the late teens to early twenties (NIDA, 
2015). Illicit drug use is higher among males when compared with females, but the gap is 
decreasing (National Center for Health Statistics [NCHS], 2017). When identified by race, 
substance use rates are highest among White individuals, followed by those identified as two or 
more races and then by those who identified as American Indian or Alaskan Native (NCHS, 
2017).  
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Demographic information regarding the geographical setting were explored to provide a 
greater understanding of substance abuse in the context of the greater community as a whole. 
Granite Wellness Centers is based in Grass Valley, one of three larger areas that comprise Nevada 
County. There are approximately 100,000 residents countywide (Nevada County Public Health 
Department, 2016). The median age of the population is 48.5 years, and the largest ethnic group 
is Hispanic at 9% (Nevada County Public Health Department, 2016). In 2014, approximately 
20% of adults and 8% of children were uninsured (Robert Wood Johnson Foundation, 2015). 
Protective factors of the larger community include rates of normal BMI (48.4%), ranking 8th out 
of 57 counties in Health Factors and 11th in Health Outcomes (Robert Wood Johnson Foundation, 
2015). However, important issues identified by community members involve financial stress, 
substance abuse, access to care, and mental health, with nearly 73% of the population noting 
substance abuse was an issue and 53% reporting it as a priority concern of the community. 
(Nevada County Public Health Department, 2016). When compared to California, Nevada 
County has higher rates of substance abuse, which is reflected in higher admission rates to 
substance abuse treatment (Shasta County Health and Human Services Agency, 2018). 
The Problem: Unintended Pregnancy 
The United States has one of the highest rates of unintended pregnancies among 
industrialized nations of the world. Approximately 45% or 2.8 million pregnancies per year are 
unplanned among women ages 15 years to 44 years (Finer & Zolna, 2016). Rates of unintended 
pregnancy in women with SUD are estimated to be nearly double that of the general population 
at 85% (Heil et al., 2011). Overall contraceptive use is lower and fewer effective methods are 
preferred among women with opioid or other SUDs (Terplan, Hand, Hutchinson, Salisbury-
Afshar, & Heil, 2015).  
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Costs related to unintended pregnancy are derived through the assumption of care 
through public funding. The majority (68%) of unplanned births are paid for through public 
insurance (Sonfield & Kost, 2015). Including prenatal care, labor and delivery, and postnatal care 
for the first year of life, costs are estimated at $12,770 per pregnancy, or $21 billion per year 
(Sonfield & Kost, 2015). Further medical costs may develop due to the increase in adverse 
maternal and fetal outcomes.  
Adverse maternal and fetal outcomes. Unfortunately, poor maternal and fetal outcomes 
are associated with unplanned pregnancies. Mothers are more likely to experience a delay in 
receiving prenatal care, have an increased risk of depression, be exposed to physical violence 
while pregnant, and are less likely to breastfeed (Office of Disease Prevention and Health 
Promotion [ODPHP], 2014). Consequences to the neonate include low-birth weight and 
increased rates of birth defects (ODPHP, 2014).  
Substance use during pregnancy is further associated with an increased risk for placental 
abruption, preterm birth, and stillbirth (Black & Day, 2016). Opioid use, in particular, is linked to 
a lack of prenatal care, fetal death, preterm labor, and intrauterine passage of meconium, and 
neonatal abstinence syndrome (Committee on Obstetric Practice & American Society of 
Addiction Medicine, 2017). Neonatal abstinence syndrome refers to a multisystem disturbance in 
neonates experienced as a result of chronic opioid exposure in utero and withdrawal at birth 
associated with irritability, poor feeding, and a high-pitch cry(Committee on Obstetric Practice & 
American Society of Addiction Medicine, 2017). Women with opioid use disorder are more 
likely to suffer from mental health conditions, experience poor nutrition, and to use other 
substances while pregnant (Committee on Obstetric Practice & American Society of Addiction 
Medicine, 2017).  
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Disparities among women. Unintended pregnancy is more common among certain 
groups of women. Age, relationship status, ethnicity, low income, and low education levels are 
noted to be factors and are addressed under the Healthy People 2020 goal to “improve pregnancy 
planning and spacing, and prevent unintended pregnancy” (ODPHP, 2014, para. 1). Barriers to 
access are more likely among the same groups of women, in addition to those who are uninsured 
(ODPHP, 2014).  
Contraceptive barriers. Barriers to use of family planning services are multifactorial. 
Cost of service, limited access to publicly-funded services or insurance coverage, lack of 
awareness, transportation, clinic location, and hours are just a few noted difficulties in obtaining 
care (ODPHP, 2014). Access is one of the primary barriers noted to affect a woman’s ability to 
obtain contraceptive services. Insurance type and the number of visits required are important 
issues to consider in offering an intrauterine device (IUD). In a retrospective analysis, fewer 
women with Medicaid, when compared with women who had private insurance, received a long-
acting reversible contraception (LARC) method in a clinic that required two visits for insertion 
(Higgins, Dougherty, Badger, & Heil, 2018). It was also noted that women with Medicaid were 
more likely to become pregnant in the year following the request for LARC (Higgins et al., 
2018). 
Women with SUD have unique barriers to contraceptive use that the general population 
may not experience, such as a past history of sexual abuse, fear of losing their existing custodial 
relationship as parents, and embarrassment regarding their substance use (Black & Day, 2016). 
Interestingly, one in four women in substance use treatment reported difficulty accessing 
healthcare providers, despite having consistent access to healthcare services, and reported they 
would utilize family planning services if offered at their treatment program (Terplan, Lawental, 
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Connah, & Martin, 2016). The perceived lack of access to healthcare services, more specifically 
family planning services, may be overcome through a formal policy change for service 
integration at addiction treatment centers.  
Patient knowledge, or lack of knowledge, in LARC options is another potential barrier to 
women with an SUD. In a survey of women receiving medication-assisted treatment, 83% 
reported they were unlikely to use an IUD due to unspecified reasons and 69% due to concerns 
regarding side effects. These women most commonly reported very little knowledge about 
LARCs (Matusiewicz, Melbostad, & Heil, 2017). These findings suggest that the population may 
benefit from further contraception education, with the potential to influence high rates of 
disinterest.   
Long-Acting Reversible Contraception 
Long-acting reversible contraception is a category of birth control methods inclusive of 
implantable and intrauterine devices. The subdermal implant and IUD are considered more 
effective than all other reversible forms of contraception, such as condoms, the pill, patch, rings, 
and the shot. Failure rates are less than 1% for the LARC methods (Office of Population Affairs, 
2019). Higher rates of continuation and user satisfaction have been demonstrated with LARC 
devices (Luchowski et al., 2014). 
Safety and efficacy. Historically, there was concern regarding the safety and 
appropriateness of IUD use in various groups of women. The safety of IUDs has been repeatedly 
demonstrated in most women, with broadening indications for appropriateness due to proven 
safety and efficacy. Age at the time of insertion, parity, and sexually transmitted infection (STI) 
risk have been thoroughly evaluated in recent literature.  
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Adolescent and younger women have traditionally failed to be recognized by providers as 
eligible candidates for an IUD. However, there have been no demonstrated differences among 
younger and older women in terms of adverse outcomes, including pregnancy, perforation, 
infection, and heavy bleeding (Jatlaoui, Riley, & Curtis, 2017). Women 25 years or younger have 
exhibited higher rates of expulsion, particularly with the copper (Cu) IUD (Jatlaoui et al., 2017). 
This is an important consideration for healthcare providers when offering counseling and 
education to younger women who request a Cu-IUD, but is not a contraindication to use. 
Another safety concern regarding IUDs is the risk of genital tract infections, potentially 
limiting the appropriateness of LARC methods in younger women and those at high risk for 
STIs. Recent research has shown that in women with STI risk factors or with an asymptomatic 
chlamydial or gonorrheal infection at the time of IUD placement were found to have no 
increased risk of developing pelvic inflammatory disease when compared to other contraceptive 
methods (Jatlaoui, Simmons, & Curtis, 2016). Women with SUD often have several risk factors 
for STI, including multiple sexual partners, unprotected sex, intravenous drug use, age, or a 
history of previous genital tract infection. This should not preclude these women as appropriate 
candidates for an IUD. Chlamydia and gonorrheal testing at the time of insertion is appropriate in 
those with risk factors for STIs, so that prompt treatment may occur with the IUD in place. 
Another subgroup of women who were not conventionally identified as candidates for 
IUDs were women who had not previously given birth. Yet, nulliparous women have not 
exhibited differences in rates of infection or expulsion when compared with parous women 
following IUD insertion (Foran, Butcher, Kovacs, Bateson, O’Connor, 2018). However, higher 
rates of insertion failure and moderate to severe pain have been noted among women who have 
not given birth (Foran et al., 2018). This is another important consideration for healthcare 
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providers to consider in contraceptive counseling and during insertion appointments. Higher 
levels of pain and potential insertion problems may be anticipated in women without children, 
but these are still rare complications.  
Best Practice Recommendations 
The American College of Obstetrics and Gynecology (ACOG, 2017), in Practice Bulletin 
No. 186, stated that LARC methods should be routinely recommended as a first-line 
contraceptive method to women due to demonstrated efficacy and safety. Women who are 
nulliparous, adolescent, or considered to be of high risk for STIs are included in the LARC 
recommendation (ACOG, 2017). The ACOG also recommends that women at high risk for STIs 
should undergo STI testing, but that insertion should not be delayed for test results. 
The National Institute of Health and Care Excellence (NICE, 2019) revised their clinical 
guidelines in 2019. They detail that even with use of a LARC method as short as 12 months, it is 
still more cost effective than oral contraceptives. The guideline aims to increase uptake of LARC 
methods through contraceptive counseling and education. In the recommendation, it is noted that 
increasing the utilization of LARC reduces the rate of unintended pregnancies (NICE, 2019).  
The Centers for Disease Control and Prevention (CDC, 2014) report “Providing Quality 
Family Planning Services” provides evidence-based recommendations regarding contraceptive 
services. Recommendations include contraceptive counseling that provides information 
regarding a broad range of birth control options and incorporates efficacy rates. The report 
advises that substance use may be a factor in correct and consistent birth control use and should 
be considered by the provider (CDC, 2014). Recommended strategies for providing 
contraception include keeping different methods available on site, so they may be offered at the 
time of visit, and the provider is reasonably certain that the woman is not pregnant (CDC, 2014). 
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However, it is also noted that even if the provider cannot be reasonably certain, the benefits of 
initiating contraception likely outweigh the risks (CDC, 2014). Some examples of criteria for 
reasonable certainty include it has been less than or equal to seven days after the start of early 
menses, has not had sexual intercourse since the start of last menses, or has correctly and 
consistently been using contraception (CDC, 2014). 
The American Academy of Pediatrics (AAP, 2014) issued recommendations for 
contraceptive use in the adolescent population. The AAP recommends contraceptive counseling 
based on efficacy rates, with LARC methods considered first-line in adolescents. AAP also 
highlights the importance of being aware of state and federal laws regarding the disclosure of 
confidential health information for minors. In the State of California, minors 12 years of age and 
older may consent to birth control, except sterilization, without parental consent under the 
California Family Code § 6925 (National Center for Youth Law, 2003). 
Available Knowledge 
Contraceptive Counseling 
Typically, contraceptive counseling and services occur within the setting of obstetrics and 
gynecology departments, family planning clinics, primary care, or sexual health clinics. There 
continues to be poor utilization of highly effective methods of birth control, known as LARC, 
among all women, and rates of unintended pregnancy remain high among women in the United 
States. This public healthcare issue has been recognized by the Office of Disease Prevention and 
Health Promotion and incorporated into the Healthy People 2020 initiatives. Increasing the 
utilization of long-acting contraceptive methods has been the focus of multiple evidence-based 
guidelines, including ACOG nationally and NICE internationally. However, according to the 
NCHS (2019), use of LARC methods among women ages 19 to 44 has only slightly increased, 
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from 8% to 11.3% since 2011, and continues to remain low. Effective contraceptive counseling 
has been proposed to improve LARC uptake among women of reproductive age. The 
effectiveness of contraceptive counseling on utilization and continuation of LARC is evaluated 
in the following literature review to improve utilization of LARC methods and to decrease the 
rate of unintended pregnancy among women who are at risk. 
PICO Question 
The population, intervention, comparison, and outcome question guiding this project is:   
 In women, how does implementation of comprehensive contraceptive counseling, compared 
with standard care, affect rates of utilization and continuation of LARC methods? 
Literature Review 
Search process. A comprehensive search of the available literature was performed using 
the databases Cochrane, CINAHL, and PubMed. Search terms included contraception or 
contraceptive, counseling, women, long-acting reversible contraception or LARC, intrauterine 
device or IUD. Limits were placed to identify the most recent and relevant literature available. 
Only articles published between 2013 and 2018, including women of reproductive age, peer-
reviewed, and published in the English language were reviewed. Articles including the male 
gender, with a sole focus on adolescents, immediately post-partum women, or post-menopausal 
women were excluded. Initial yield was 37 articles. After articles were reviewed for applicability 
and duplicates, 13 remained. The applicable articles were then evaluated with the Johns Hopkins 
Nursing Evidence-Based Practice Research Evidence Appraisal Tool and prioritized by quality of 
evidence (Dang & Dearholt, 2017). Lastly, articles selected were organized in a summary table 
(see Appendix A). 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  16 
 
LARC uptake. A landmark study, known as the Contraception CHOICE Project, 
examined the effect of reducing barriers to LARC methods, with a larger goal of reducing 
unintended pregnancies (Birgisson, Zhao, Secura, Madden & Peipert, 2015). Over 9,000 women 
of reproductive age received tiered contraceptive counseling to increase their knowledge and 
awareness of LARC methods and were then provided free contraception of their choosing. When 
barriers, including education, cost, and access, were reduced, 75% of women selected a LARC 
option (Birgisson et al., 2015). Interestingly, the authors also found that women who selected a 
LARC were more likely to report continuation at 12 and 24 months than those who had selected 
other methods (87% versus 57%; 77% versus 44%, respectively). Birgisson et al. (2015) 
demonstrated that women prefer long-acting contraception and are more likely to continue use 
than with other non-LARC methods when provided contraception counseling with barrier 
reduction.  
After implementing a standardized provider training, Gibbs et al. (2016) explored the 
effect of contraception counseling among nulliparous and adolescent women. A total of 1,500 
young women ages 18 years to 25 years were enrolled in either an intervention or a control clinic 
in a cluster randomized trial, with 12-month follow-up. Among the intervention group, women 
were more likely to receive contraceptive counseling and were nearly twice as likely to select a 
LARC than the control group (Gibbs et al., 2016). Notable findings included that nulliparous 
women were less likely to receive contraceptive counseling from healthcare providers (adjusted 
odds ration [aOR]=.57; 95% confidence interval [CI]: .42-.79) or select a LARC (aOR=.53; 95% 
CI: .37-.75) than women who had given birth (Gibbs et al., 2016). However, when older 
adolescents were compared with young adult women, they had similar rates of counseling 
(aOR=.85; 95% CI: .63-1.15), LARC selection (aOR=.86; 95% CI: .64-1.17), and utilization 
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(adjusted hazard ratio [aHR]=.94; 95% CI: .69-1.27). Gibbs et al.’s findings highlight the 
effectiveness of contraceptive counseling on LARC selection among young women. However, 
the results also suggest that parity may influence a provider’s engagement in contraceptive 
counseling regarding LARC methods. 
Harper et al. (2015) evaluated the influence of evidence-based training for providers 
regarding counseling and IUD insertion on LARC uptake. The cluster randomized trial was 
performed among 40 clinics throughout the United States and included 1,500 enrolled women 
ages 18 years to 25 years. Provider training at the intervention clinics included method 
knowledge, counseling, and placement, while control clinics received no training. In the 
intervention group, 71% of women reported their provider discussed LARC, compared to only 
39% in the control group (Harper et al., 2015). Long-acting contraception was selected by 27.9% 
of women in the intervention group, compared with 16.8% in the control group (Harper et al., 
2015). Again, the results of this study support effective contraceptive counseling on increased 
LARC uptake. 
Continuation rates. Contraceptive counseling has also been suggested to influence rates 
of IUD continuation. Reasons for discontinuation of an IUD include irregular menstrual 
bleeding, cramping and pelvic pain, expulsion, systemic effects, or desired pregnancy. 
Discontinuation rates were evaluated through the Contraceptive CHOICE Project. Hormonal 
IUDs were noted to have 7.3% discontinuation within the first six months, compared with 8.0% 
for the Cu-IUD (Grunloh, Casner, Secura, Peipert, & Madden, 2013).   
Raifman, Barar, and Foster (2017) investigated the effect of counseling regarding IUD 
self-removability on IUD uptake, satisfaction, and continuation. The six-month study was 
divided in two phases. During the first three months, the counselor provided standard 
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contraceptive counseling, with the addition of IUD self-removal counseling during the last three 
months. Women who selected an IUD were then compared among the control and intervention 
group for differences in the previously mentioned outcome variables. There were no significant 
differences in IUD uptake, satisfaction, or discontinuation rates among women who had received 
counseling that included self-removal compared with those who had not received this counseling 
(Raifman et al., 2017). Yet, knowledge of self-removability was high prior to intervention in both 
groups (27% control, 43% intervention). An additional finding was that one-third of women who 
had considered IUD removal reported barriers to removal, such as provider discouragement and 
appointment availability (Raifman et al., 2017). Self-removal is an important topic to consider in 
contraceptive counseling, especially when a woman expresses concern over contraceptive 
control or barriers to removal.  
While satisfaction with LARC methods is higher than other methods of birth control, 
with comparatively high rates of continuation, the role of intensive contraceptive counseling on 
discontinuation rates was undetermined. Intensive and non-intensive counseling were evaluated 
for effect on discontinuation rates of three LARCs due to bleeding problems (Modesto, 
Bahamondes, & Bahamondes, 2014). Participants included 297 women who had received either 
a hormonal IUD, non-hormonal IUD, or implant. No significant differences were seen in 
discontinuation rates due to bleeding disturbances in women who had received intensive 
counseling compared with standard counseling (Modesto et al., 2014). Premature discontinuation 
of an IUD may lead a woman to choose a less effective form of birth control and increase her 
risk for unintended pregnancy. Although intensive versus standard counseling did not reduce the 
already low rates of discontinuation attributed to bleeding disturbances, counseling about what to 
expect following LARC initiation is an important strategy to prevent premature discontinuation.  
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Rationale 
Conceptual Framework 
The conceptual framework guiding this project is the Clinical-Community Relationships 
Evaluation Roadmap. Patients, clinics/clinicians, and community resources, and their interplay in 
delivering clinical preventative services, are at the center of this framework (Agency for 
Healthcare Research and Quality [AHRQ], 2013). There are three didactic relationships, which 
are the clinic/clinician-patient relationship, clinic/clinician-community resource relationship, and 
patient-community resource relationship (AHRQ, 2013). The purpose of the roadmap is to 
design and implement relationships, with the goal of providing clinical preventative services 
specifically through the clinical-community relationship (AHRQ, 2013). The roadmap was 
developed initially for primary care clinics to expand their linkages with community resources in 
providing preventative services, but it is applicable in a broader context, as well (AHRQ, 2013).  
The clinic/clinician provides accessibility of reproductive services to appropriately 
identified patients. As a result, barriers to access are mitigated. The interrelationship between 
clinician and patient is influenced by trust, shared decision-making, and support of patient self-
management (AHRQ, 2013). There are currently three healthcare providers on site, including a 
medical doctor, nurse practitioner, and physician’s assistant, who are well-equipped to provide 
contraceptive counseling and services. Both the clinic stakeholders and clinicians recognize the 
need for women with SUD to have increased access to family planning services. Expanding on 
the currently offered initial screening of contraception use, the addition of contraceptive 
counseling and same-day LARC services act as both a valuable community resource and a 
clinical preventative service.  
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Patients in the roadmap are the clients admitted for residential or outpatient treatment. 
Clients requesting medication-assisted or residential treatment require medical evaluation and 
clearance in the on-site clinic, providing the prime opportunity for the incorporation of family 
planning services. Patient perceptions and attitudes impact contraceptive preference and 
attitudes, with the potential to affect the patient-community resource relationship (Matusiewicz 
et al., 2017). Patient barriers, including limited or incorrect knowledge, are addressed through 
counseling that is effective, efficacy-centered, and respective of patient autonomy.  
The relationship between clinic and community resource is traditionally affected by a 
referral process, collaboration among providers, and feedback mechanisms between the two site 
entities (AHRQ, 2013). Due to the incorporation of the community resource within the clinic, 
referral processes and collaboration between external entities for the services are limited. The 
framework was utilized to develop a project intervention to enhance the delivery of a clinical 
preventative resource by the existing providers on site due to the rural location and lack of 
outside community resources. 
The project intervention included a LARC training workshop for providers, with 
evidence-based clinical practice recommendations on LARC methods and a skills portion for 
IUD and implant procedures. The aim of the intervention was to enhance the providers’ 
knowledge and procedural skills for LARC counseling and initiation in preparation for offering 
services on site. Provider training was selected to target the relationship between provider and 
client to increase uptake of LARC utilization through contraceptive counseling. Multiple studies 
have demonstrated LARC barrier reduction, including contraceptive counseling, to increase 
LARC uptake among women with underutilization (Birgisson et al., 2015; Gibbs et al., 2016; 
Harper et al., 2015). 
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The integration of contraceptive services within an addiction medicine center highlights 
the need for effective relationships among patients, clinic/clinicians, and community resources in 
addressing high rates of unintended pregnancy. This DNP project utilized the Clinical-
Community Relationships Evaluation Roadmap to identify and address a crucial clinical 
preventative service lacking for women with SUD. Barriers to patients and providers were 
considered in the design of this project to improve the key didactic relationships among the 
clinic/clinician, community resource, and the patient. An intervention to improve the key didactic 
relationships was implemented through a LARC provider training workshop to enhance provider 
knowledge and skill in providing contraceptive services. Outcome evaluation was assessed 
through a pre/post assessment on provider confidence and readiness for providing contraceptive 
services at the clinic. With increased confidence in LARC knowledge and procedural skill, the 
providers will be adequately prepared to enhance utilization of LARC methods on site.  
AIM Statement 
The primary aim of this quality improvement project is to reduce rates of unintended 
pregnancy among women with SUD through the development of a pilot project to integrate 
contraceptive services in addiction medicine treatment. Emphasis was placed on effective 
contraceptive counseling to increase uptake of highly-effective contraceptive methods.  
Project Goals  
1. Research and design a pilot program for the delivery of contraceptive counseling and 
LARC services at Granite Wellness Centers.  
2. Plan for a future pilot program rollout of contraceptive services at Granite Wellness 
Centers. 
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Project Objectives  
1. Conduct a feasibility analysis, to include an evaluation of the current literature 
regarding contraceptive counseling methods on LARC uptake and continuation; 
perform a site evaluation to determine resource readiness; conduct a women’s focus 
group to assess current attitudes, beliefs, and needs regarding contraception; and 
identify two possible funding sources for pilot initiation. 
2. Design and provide an interdisciplinary LARC training workshop for the medical 
staff at Granite Wellness Centers to enhance readiness for service integration. 
3. Present all findings of the feasibility study to the board members at Granite Wellness 
Centers. The presentation will include recommendations for contraceptive services 
derived from the feasibility analysis, a proposed timeline for implementation when 
funding is obtained, and a financial analysis including a proposed budget and return 
on investment. 
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Section III: Methods 
Context 
There is an unmet need to enhance access of contraceptive services to women with an 
SUD. Offering contraceptive services concurrently with substance use treatment, with same-day 
services, provides the greatest opportunity to eliminate potential barriers to contraceptive use. 
Ultimately, birth control methods, known as LARC, are ideal for this patient population due to 
the highest rates of efficacy among all birth control options.  
The selected site for this DNP project is Granite Wellness Centers, a non-profit in the city 
of Grass Valley. The clinic is located in a rural area of northern California. The stated mission 
includes, “to provide a full spectrum of programs focused on reducing the social, health, and 
financial impact on our families and children from all types of drug abuse” (Granite Wellness 
Centers, 2019, para. 2). The site provides comprehensive addiction treatment services, including 
residential, outpatient, and medication-assisted treatment. Presently, contraceptive services are 
not offered on site, and patients are referred out to their primary care provider or other 
community resource for healthcare needs outside of substance use treatment (see Appendix B. 
Gap Analysis).  
While contraceptive services are largely covered by private and public insurance 
providers, the clinic site is not currently contracted for billing and reimbursement for medical 
services outside of substance use treatment. The clinic was actively in the process of expanding 
services provided on campus. Therefore, it was mutually agreed upon by the site stakeholders 
that priority should first be placed on conducting a feasibility analysis, and a letter of support 
was issued by the organization (see Appendix C). The goal of the feasibility evaluation was to 
determine readiness for the integration of LARC services in preparation for a future pilot project, 
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when services and related costs are covered or a funding source is available. In addition to the 
feasibility analysis, this DNP student designed and executed an interdisciplinary LARC training 
workshop. The training was conducted in part by IUD and implant device representatives to 
provide hands-on skills training for the medical providers and education about their respective 
products. The pharmaceutical representatives provided their time and training at no cost. 
GANTT  
The timeline of this DNP project is detailed through the use of a GANTT chart (see 
Appendix D). This DNP project occurred over an 11-month period from February 2019 until 
December of 2019. Following the conceptual phase and project approval was the design phase. 
Details of the design phase included design of the surveys for the current client focus group, 
provider training pre- and post-engagement assessment, and staff readiness for change survey, 
which occurred in August and September of 2019. The women’s focus group and site assessment 
were then conducted, while funding sources and other resources were explored. The main 
intervention included the two-part provider LARC workshop offered in November and 
December of 2019. A final presentation was prepared and delivered to the board members at 
Granite Wellness Centers, including a summary of findings and recommendations for a pilot 
project. Lastly, the project evaluation was closed with the final report preparation. Further project 
details were organized in a work breakdown structure and communication matrix (see Appendix 
E and Appendix F).  
Strengths, Weaknesses, Opportunities, Threats 
The strengths, weaknesses, opportunities, and threats of this project were acknowledged 
to aid in the identification of potential external and internal influences (see Appendix G). 
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Strengths. The internal strengths of this project include the on-site medical clinic with 
patient rooms. The clinic has two patient rooms available for providers to offer contraceptive 
counseling and services during medical appointments. There are three providers on site with 
prior experience in IUD insertion. Also, the mission of Granite Wellness Centers is in line with 
the aim of this project to reduce healthcare disparities among women with SUD. Lastly, the staff 
are regularly engaged in process improvement meetings and aware of organizational change. 
Weaknesses. There are also internal weaknesses to this project. An initial pilot project 
requires a funding source or internal medical billing changes at the clinic, which involves 
continued communication with the billing department and a search for potential funding 
opportunities. Also, co-occurring service expansion places additional strain on the clinic and its 
resources, with the potential to halt pilot initiation until the other service expansions are 
completed. Potential weaknesses that will require continued evaluation are the upfront supply 
cost and time factors related to same-day contraceptive initiation. The healthcare providers are 
responsible for all residential admissions, overseeing group medication-assisted treatment 
meetings and requested appointments from both residential and medication-assisted treatment 
clients. Issues and appointments related to substance use will be prioritized and may affect the 
ability to deliver LARC services when requested.  
Opportunities. This quality improvement project provides anticipated external benefit, 
as well. The first potential opportunity is the ability to reduce rates of unintended pregnancy 
among women seeking substance use treatment. Adverse maternal and fetal outcomes associated 
with unplanned pregnancy will also be reduced. There is an additional opportunity for women to 
receive comprehensive, evidence-based contraceptive counseling. Women utilizing LARC 
methods have higher satisfaction with method choice and greater control over family planning 
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due to the highest efficacy rates. With success of the pilot initiation of integrated services at the 
Grass Valley campus, expanded services may be added to other campuses in northern California.  
Threats. The potential inability to obtain external reimbursement for services rendered is 
the largest threat, as the clinic is not currently set up to bill for medical services outside of 
substance use treatment. If medical reimbursement is obtained, another external threat is the 
repeal of the Affordable Care Act. The Affordable Care Act is responsible for expanding 
coverage of contraceptive services to patients without cost-sharing. The cost of an IUD alone is 
substantial and can range from $400 to $700, which would be prohibitive to patients without 
coverage. Another external threat is the development of other clinics or sites offering competing 
services, with the potential to reduce client acquisition at the site. 
Cost-Benefit Analysis 
The proposed budget for the pilot rollout is detailed here for a three-month estimate. 
Operational expenses of this project include employee salary and benefits, medical supply costs, 
and laboratory testing supplies and fees. Contraceptive services are largely reimbursable through 
changes made by the Affordable Care Act, ensuring coverage for contraceptive services without 
cost-sharing to individuals. Supply costs for IUD insertion include a speculum, lubricant, 
tenaculum, antiseptic, uterine sound, scissors, sterile gloves, ring forceps, gauze, cotton swabs, 
chucks, sanitary napkins, and sterile drapes (University of California San Francisco, Bixby 
Center for Global Reproductive Health [UCSF], 2015). The average IUD cost is $629.75 when 
purchased from the manufacturer and disposable insertion kit price is $44.21 (UCSF, 2015). 
Training time (2.5 hours to 3 hours) and provider time to complete screening, education, 
documentation, insertion, and follow-up are estimated to be at a minimum 60 minutes per patient 
($51.15 hourly). Laboratory testing for basic STI screening is $55 and $1.60 per test for urine 
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pregnancy testing. Performing pelvic examination and IUD insertion also requires specialized 
equipment. Fixed asset purchases include stirrups ($1,395) and an illumination system ($299). 
Total costs expected over a three-month pilot project, including the operational and fixed asset 
costs for 15 patients, are $17,390. However, as previously mentioned, these services are 
reimbursable. Reimbursement may be obtained for the IUD and other supply costs, insertion, 
surveillance, and an evaluation and management visit for time spent counseling patients (UCSF, 
2015).  
Due to the high rate and commensurately high costs associated with unintended 
pregnancy, there has been a large national initiative to improve the reimbursement rates of LARC 
methods. The majority of clients receiving care at Granite Wellness Centers have state-funded 
insurance through the Medi-Cal Program. Reimbursement rates currently listed on the 
Department of Healthcare Services(2019) site are itemized as $166.20 for insertion, $808.50 for 
the Cu-IUD and $953.51 for the five-year levonorgestrel-containing IUD, a $12 dispensing fee, 
$57.20 for contraceptive counseling encounter and follow-up encounter, $31.17 for each 
chlamydia and gonorrhea testing, and $2.80 for a urine pregnancy test. 
Return on Investment 
A return on investment (ROI) is traditionally calculated by dividing the net projected 
benefit by total program cost and then multiplying by 100. Upon pilot initiation, finalized 
program costs can be appreciated and included in the ultimate calculations. Projected benefit 
with initiation of contraceptive services is considered in the avoidance of unintended pregnancy. 
Current cost avoidance estimates, including prenatal care, birth, and the first year of life care, are 
$12,770 (Sonfeld & Kost, 2015). Additional costs, including medical treatment for unintended 
pregnancy-related adverse outcomes in women with SUD, should also be considered. The 
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average cost for the Cu-IUD and hormonal IUDs are $1,136.84 and $995.02, respectively. For 
each dollar spent on IUD services, there is an expected $5 cost savings for the Cu-IUD and $4.89 
for the hormonal IUD (Foster et al., 2013). Therefore, for each woman who receives an IUD for 
contraception, there is an expected cost savings of $5,330. Cost savings can be achieved with the 
prevention of one unintended pregnancy (see Appendix H).   
Interventions 
Feasibility Analysis 
A feasibility analysis was conducted to determine site preparedness for a contraceptive 
service integration pilot project. Components of the feasibility analysis included a site survey to 
develop a comprehensive inventory list and identification of additional supplies required, a 
women’s focus group exploring current attitudes to contraception, staff readiness for change 
survey, and identification of possible funding sources. In preparation for the anticipated pilot 
project, necessary resource documents were identified and used with permission from the 
Reproductive Health Access Project to cover the establishment of new policies and procedures 
(see Appendix I), consent forms, billing resources, documentation aids, supply lists, and patient 
education materials (see Appendix J).  
Site survey. The site survey was performed utilizing the site readiness checklist 
(Reproductive Health Access Project, n.d.; see Appendix K). Issues and requirements assessed 
included considerations for the facility and administrative and clinical areas. The site presently 
met the facility requirements for storage space for devices, sterile equipment and non-sterile 
equipment, and sterilization of equipment using an autoclave. It was noted that a policy and 
procedure was not currently established for the use of the autoclave, but one was being 
developed. Administrative considerations included chart note templates for IUD insertion and 
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removal, up-to-date billing and coding codes, system appointment for scheduling, and system for 
ordering and tracking supplies. The site had two active medical supply vendors with the 
capability to order LARC supplies. Clinical considerations met were the establishment of an IUD 
protocol and procedure, consent forms, patient education materials, patient aftercare information, 
and malpractice coverage. Also, a patient satisfaction survey was developed by this DNP student 
to aid with quality assurance when the pilot is initiated (see Appendix L). 
There were some requirements not met or completed at the time of site survey. The site 
has two exam rooms with exam tables. Unfortunately, the exam tables are not height adjustable 
and do not have foot holders contained within them to allow lithotomy positioning. However, the 
clinic had budgeted to purchase a new exam table and were working towards obtaining one with 
the aforementioned requirements. Also, the site did not have IUD insertion and removal supplies 
on site. A supplies list was obtained as a reference guide for pilot initiation. As previously 
mentioned, billing practices were not established for medical services. 
Women’s focus group. Current female clients of Granite Wellness Centers were included 
in a focus group on contraception and participated in a survey of current attitudes, knowledge, 
and concerns regarding contraception. This DNP student provided a comprehensive, efficacy-
based, contraceptive educational session, with time allowed for additional questions. Each birth 
control method was briefly reviewed, starting with LARC methods and ending with the least 
effective methods. Side effects, adverse effects, mechanism of action, and efficacy were 
discussed. A paper survey was administered to each participant to collect additional information, 
including barriers to contraception, concerns regarding birth control, existing knowledge, and 
interests and concerns regarding the addition of family planning services within substance use 
treatment (see Appendix M). 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  30 
 
Staff readiness. Staff buy-in is a vital component to organizational change. Therefore, an 
intervention to assess staff readiness for the integration of contraceptive services on site was 
utilized to make appropriate recommendations to the board committee. A staff survey was 
designed to address the five major organizational components of change, including the need for 
change, leadership and management, attitudes to change, communication, and preparation for 
change (see Appendix N). 
Funding sources. Funding sources were explored through a grant database search. 
Grants were evaluated for applicability and appropriateness of the pilot project to meet the listed 
grant criteria. Grant organizers were contacted when additional information was required. 
Contraceptive services met the criteria of multiple open grants; however, they did not have an 
open application cycle at the time the research was conducted. Also, the process for medical 
contracting was actively pursued by the organization. The practice manager submitted a 
contractual application in September 2019. In anticipation of future medical reimbursement, 
billing and reimbursement were further investigated through a cost-benefit analysis and 
estimated ROI.  
LARC Interdisciplinary Training Workshop 
A staff training course was created to provide the healthcare providers and medical staff a 
review of current best practice recommendations regarding LARC utilization, skills on IUD 
insertion with vaginal simulators, contraceptive counseling, and Nexplanon training and 
certification. This DNP student coordinated with the representatives of Bayer, CooperSurgical, 
and Nexplanon to provide a hands-on component to the workshop for skill practice and 
development. The training was provided on two separate dates due to clinical providers’ time 
constraints and the availability of the representatives.  
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The first training date was provided by this DNP student and a Bayer representative. The 
Bayer representative included an overview of their available levonorgestrel-containing devices 
(i.e., Mirena, Skyla, and Kyleena), with a combined skills portion on vaginal simulators for IUD 
insertion. The Bayer representative provided patient clinical education resources, noted the 
ability to stock devices without upfront costs to the clinic, and the ability to obtain replacement 
devices without additional cost if insertion failure occurs. This student presented evidence-based 
practice recommendations regarding LARC use, safety and efficacy, and contraceptive 
counseling through a PowerPoint presentation (see Appendix O). This DNP student also 
provided a folder containing applicable resources for each attendant that included a billing codes 
tool, birth control efficacy chart, IUD insertion and removal note templates, IUD consent form, 
an IUD patient take-home sheet, and copy of presentation slides (see Appendix P). All medical 
staff discussed and identified their role in enhancing contraceptive awareness through 
contraceptive counseling. The nursing staff recognized opportunities to provide and reinforce 
patient teaching within the residential treatment center. Additional topics discussed were 
consequences of unintended pregnancy and barriers to contraceptive use in the general 
population, as well as in women with SUD. A pre- and post-test were utilized to assess provider 
confidence and readiness in providing contraceptive counseling and IUD insertion with the 
Bayer products (see Appendix Q).  
The second training date was conducted by a representative from Nexplanon on the 
subdermal implant. The Nexplanon representative offered a two-hour training course regarding 
the subdermal implant and removal procedure. Upon completion, the providers were given a 
certification for Nexplanon insertion and removal. A pre- and post-test were utilized to assess 
provider confidence and readiness in providing the Nexplanon device. Upon completion of the 
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training, a training evaluation form was administered to each participant to gather information 
regarding participant satisfaction and training quality and relevance (see Appendix R). Practice 
kits, including an arm simulator and two implant injectors, were also given to the healthcare 
providers to keep for additional practice following the training. 
Presentation 
The project culminated with a presentation to the board members at Granite Wellness 
Centers. The final presentation included recommendations for contraceptive services derived 
from the feasibility analysis, a proposed timeline for project implementation when funding is 
obtained or billing practices are established, and a financial analysis including a proposed budget 
and ROI. Data obtained from the women’s focus group, staff readiness for change survey, and 
provider training were included in the project recommendations. 
Study of the Methods 
The long-term goal of this project is to prevent unintended pregnancy through the 
addition of contraceptive services within substance use treatment, emphasizing LARC methods. 
However, due to the current inability to bill for medical reimbursement at the clinic location, 
short-term outcomes were established to prepare the clinic for future pilot initiation. The short-
term goals established to evaluate this quality improvement project were to conduct a feasibility 
analysis of the site, develop an interdisciplinary LARC training workshop, and to present 
findings of the feasibility analysis to the board committee in preparation for future pilot 
initiation. Surveys were administered to the women at the focus group, providers pre/post the 
LARC training workshop, and medical staff to determine readiness for change. Survey data were 
collected and analyzed with Microsoft Excel analysis tools and Survey Monkey. All data 
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collected were used to summarize findings and make appropriate recommendations for pilot 
program initiation to the board members.   
Measures and Methods of Evaluation 
For this project, outcome measures were completing the components of the feasibility 
analysis, LARC interdisciplinary training workshop, and final presentation with 
recommendations for pilot project.  
The feasibility analysis included a literature review, site assessment, women’s focus 
group, staff readiness for change survey, and funding source identification.  A survey of the 
clients attending the women’s focus group was administered to gather more information from the 
current clients regarding contraceptive use, attitudes, and knowledge to include in the board 
committee presentation. The women’s focus group survey included three open-ended questions 
and four multiple choice items. Questions included: 1. What barriers do you experience in 
obtaining birth control/contraceptive services? 2. What are your concerns regarding birth 
control? 3. What community organizations are you aware of that provide free/low cost birth 
control? 4. What resources regarding contraceptive care would benefit you the most? 5. Would 
you utilize birth control if offered at no cost while receiving treatment? 6. Have you ever 
received comprehensive contraceptive counseling regarding all birth control options available to 
you? 7. Which birth control options would you be most interested in receiving? 
The staff readiness for change survey was administered to all medical staff following the 
LARC training workshop. Readiness was assessed through agreement in responses to 16 
statements corresponding to different areas of organization change. Likert-type responses ranged 
from 1 for strongly disagree to 5 for strongly agree. Statements were as follows: 1. There is need 
for organizational change to expand services to include contraceptive services. 2. I am aware of 
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the reasons why change is needed within the organization. 3. Expanding the services provided to 
the clients is appropriate and achievable. 4. I am aware that the organization is considering 
expanding services offered to include contraceptive services. 5. I understand the need to include 
contraceptive services in the services offered in all clinical visits including intake appointments 
and follow-ups. 6. Management is committed to providing support to staff during periods of 
change. 7. I am able to discuss changes with leadership and management. 8. Providing 
contraceptive services will benefit the organization. 9. I am supportive of the integration of 
contraceptive services into clinic appointments. 10. I know how my role can help make the 
expanded services successful. 11. There is adequate consultation with staff when change occurs. 
12. Staff communication is reliable and well-timed. 13. I am adequately trained to offer 
contraceptive services within my role and scope of practice. 14. I have the resources I need to 
provide contraceptive services within my role. 15. I am confident in my ability to provide 
contraceptive services to all clientele. 16. Overall, I believe contraceptive services will be 
advantageous for the clientele participating in substance use treatment and the larger community.  
The interdisciplinary LARC training workshop was designed to enhance readiness and 
confidence for providing contraceptive counseling and LARC procedures among medical staff. 
The outcome of the LARC training workshop was assessed through an identical pre- and post-
engagement survey administered to the healthcare providers. Readiness and confidence 
regarding contraceptive counseling and IUD insertion were measured through an eight-item 
assessment, based on a 5-point Likert scale. Possible responses assessed agreement with posed 
confidence and readiness statements and included: strongly agree (5), agree (4), neutral (3), 
disagree (2), and strongly disagree (1). There was also a comment section included at the end of 
each survey to obtain additional information from participants. Outcomes for the LARC provider 
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workshop were evaluated based on the following statements: 1. I am comfortable providing 
comprehensive contraceptive counseling consistent with current practice recommendations. 2. I 
am confident in identifying all LARC eligible candidates. 3. I feel prepared to counsel patients 
about LARC effectiveness and safety. 4. I feel confident in counseling patients about LARC 
insertion and follow-up. 5. I feel comfortable with IUD insertion. 6. I am adequately prepared to 
insert an IUD. 7. I have sufficient previous experience with IUD insertion. 8. Hands-on skills 
training is an effective method to prepare for IUD insertion. 
The outcome of the second LARC training workshop was similarly assessed through an 
identical pre- and post-engagement survey administered to the healthcare providers. Readiness 
and confidence regarding Nexplanon counseling, insertion, and removal were assessed through a 
four-item assessment, based on a 5-point Likert scale. Possible responses assessed agreement 
with posed confidence and readiness statements and ranged from strongly agree (5) to strongly 
disagree (1) with additional comment section at the end. Outcomes for the second LARC 
provider workshop were evaluated based on the following statements: 1. I feel comfortable with 
Nexplanon insertion and removal. 2. I am adequately prepared to provide Nexplanon counseling, 
insertion, and removal. 3. I have sufficient previous experience with providing the subdermal 
implant. 4. Hands-on skills training is an effective method to prepare for Nexplanon insertion 
and removal.   
Methods for assuring data quality and accuracy included a post-training follow-up survey 
with statements about training relevance, effectiveness, satisfaction, and quality. The first section 
assessed satisfaction with different aspects of the training. Likert scale responses were very 
satisfied (5), satisfied (4), neutral (3), dissatisfied (2), and very dissatisfied (1). Possible Likert 
scale responses to posed statements regarding training content, relevance, organization, quality, 
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and time included: strongly agree (5), agree (4), neutral (3), disagree (2), and strongly disagree 
(1). A comments section was also available for additional information.  
Analysis 
The women’s focus group data were analyzed utilizing Survey Monkey. Paper surveys 
were disseminated to all women in attendance. The women’s focus group survey responses were 
manually entered into SurveyMonkey for analysis. Summary statistics, including frequencies and 
means, were calculated. Responses to open-ended questions were ranked categorically for 
similarity, with subsequent ranking by frequency. Select all that apply formatted questions were 
categorized by frequency of response. Mean responses were calculated for questions with one 
answer selection. 
For evaluation of the LARC training workshop, qualitative data were collected through a 
pre- and post-assessment survey for both training sessions. The Likert scale responses were 
numerically categorized ranging from strongly disagree (1) to strongly agree (5). The responses 
assessed agreement with confidence and readiness-based questions surrounding contraceptive 
counseling and LARC utilization. Responses were manually entered into Excel, where the mean 
response was calculated for each of the seven questions on the pre- and post-surveys. The mean 
percent change (delta Δ) was calculated between the pre- and post-assessment responses to 
measure the impact of the LARC workshop for medical providers. A post-training evaluation was 
administered to all staff to evaluate training content, relevance, and delivery. 
The staff readiness for change survey was administered at the LARC workshop to the 
medical staff. The survey consisted of 16 statements, with Likert scale responses ranging from 
strongly agree (5) to strongly disagree (1). The responses assessed agreement with posed 
statements assessing different aspects of the change process as related to this quality 
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improvement project. Survey responses were manually entered into Excel. Summary statistics 
including the mean (M) and standard deviation (SD) were calculated for each statement.  
Ethical Considerations 
The University of San Francisco DNP department determined that this project met the 
criteria for an evidence-based practice change project, as outlined in the DNP project checklist, 
and was approved as non-research (see Appendix S). The primary Jesuit value of Men and 
women for and with others is represented in this project. The project intends to expand currently 
offered services to women in substance use treatment. This project identified a critical healthcare 
disparity, with a goal to work with the current client population to reduce healthcare disparities 
and barriers to care. 
Ethical principles considered in this project include beneficence and respect for 
autonomy. Beneficence refers to promoting the patient’s wellbeing. The goal of this project is to 
help motivate patients to take control of their reproductive health and engage in contraceptive 
planning. There is an increased risk of poor maternal outcomes associated with unplanned 
pregnancies. Medical providers in addiction medicine are primed for the opportunity to address 
contraceptive use when contact is frequent and closely monitored. Respect for autonomy is also 
imperative in this project. It is essential for the client to make her own informed decision when 
participating in birth control selection, once provided with all available options and information. 
It is the provider’s responsibility to provide comprehensive contraceptive counseling free from 
any potential bias and to respect the choice of the client.  
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Section IV: Results 
Qualitative data were collected through surveys disseminated at the women’s focus group 
and LARC provider training workshop. The results from the surveys are discussed in detail here. 
Women’s Focus Group 
The women’s focus group was a 60-minute session held in the residential treatment 
program building at Granite Wellness Centers in September 2019. All women in attendance were 
participating in inpatient substance use treatment. Only 10 of the 13 participants completed 
surveys, and it was noted that three of the women were post-menopausal. Regarding barriers to 
obtaining contraception, interestingly, six of 10 respondents did not feel they currently had any 
barriers, noting, “none,” “N/A,” and “none at this time.” The most common contraception 
concerns were identified by participants from a select all that apply question, which included 
side effects, fertility, access, ease of use, hormones, bleeding patterns, cost, effectiveness, and 
other. Most commonly selected were side effects (7/10), hormones (4/10) and access (3/10). Ease 
of use, bleeding patterns, and cost were less frequently reported concerns. All respondents had 
knowledge of an existing community resource that offered contraception for free or at a reduced 
cost. Interestingly, the community resource identified by nine of the 10 participants was Planned 
Parenthood, but the nearest available clinics were approximately one hour away. When asked 
what resources regarding contraceptive services would be most beneficial, respondents most 
commonly selected STI testing (3/10) and free birth control (3/10). Nine of the 10 participants 
reported they would utilize birth control if offered at no cost while receiving substance use 
treatment. An unexpected finding was that six of the 10 women reported they had never 
previously received comprehensive contraceptive counseling regarding all birth control options, 
one respondent was unsure, while the remaining three respondents reported they had received 
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contraceptive counseling. Lastly, the women reported which birth control options they would be 
most interested in receiving from a select all that apply question, with the hormonal IUD, non-
hormonal IUD, emergency contraception, condoms, birth control pills, Depo-Provera shot, 
Nexplanon (implant), and other listed. The non-hormonal IUD was selected most often (5/10), 
followed by condoms (3/10), hormonal IUD (2/10), and birth control pills (2/10). 
LARC Training Workshop 
Part 1 
Two providers (physician’s assistant and family nurse practitioner) of the three medical 
providers at the site attended the LARC training workshop with hands-on skills training. Both 
participants had previous experience with IUD insertion. Results of the pre and post mean data 
are displayed in Table 1. 
Table 1 
Survey Results 
Survey S1 S2 S3 S4 S5 S6 S7 S8 
Pre-Survey Mean 3.0 3.0 2.5 3.0 2.5 2.5 3.0 3.5 
Post-Survey Mean 4.5 4.5 4.5 4.5 4.0 4.0 3.5 4.5 
% Change 33.33 33.33 44.44 33.33 37.50 37.50 14.20 22.22 
Note. S denotes survey statement number. 
 
There was a 33.33% increase in provider comfort with providing contraceptive 
counseling, confidence in identifying LARC eligible candidates, and confidence in counseling 
clients about the LARC insertion procedure and follow-up. Statement 3 showed the greatest 
improvement, with a 44.44% increase in provider preparedness in providing counseling 
regarding LARC safety and efficacy. Both providers stated they agreed with statements of 
feeling comfortable and prepared for IUD insertion following training, with a 37.5% increase. 
Provider attitude on whether hands-on skills training was an effective method to prepare for the 
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procedure increased 22.22% following the training. No additional comments were given on the 
assessments.  
Part 2 
Four providers attended the LARC training workshop with hands-on skills training. Two 
providers were from outside clinics and medical settings. It was noted that one attendee had 
previously been certified in Nexplanon insertion in 2014 and was attending the training as a 
training update and refresher. Results of the pre and post mean data are displayed in Table 2. 
Table 2 
Survey Results 
Survey S1 S2 S3 S4 
Pre-Survey Mean 2.0 3.5 3.0 3.75 
Post-Survey Mean 4.75 4.75 4.0 5.0 
% Change 57.89 26.31 25.0 25.0 
Note. S denotes survey statement number. 
 
The greatest increase was exhibited in provider comfortability with Nexplanon insertion 
and removal post training. Statement 2 reflected a 26.31% increase in provider preparedness to 
provide Nexplanon specific counseling, insertion, and removal. Provider attitude on whether 
hands-on skills training was an effective method to prepare for the procedure increased 25.0% 
following the training. There was similarly a 25.0% increase in agreement with the posed 
statement, “I have sufficient previous experience with providing the subdermal implant”. No 
additional comments were given on the assessments. Inferential analysis was not conducted due 
to limitations from the small sample sizes. 
Readiness for Change Survey 
Ancillary medical staff attended the in-service, including the practice manager, two 
medical assistants, one licensed vocational nurse, and one registered nurse. Following the 
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training, all medical staff were administered a survey to assess readiness for change. Ratings 
from the staff members are displayed in Figure 1.  
 
Figure 1. Staff readiness for changes results. 
 
Statements 1, 2, 3, 4, and 5 assessed staff recognition for the need for change to integrate 
contraceptive services within the organization, with largely favorable responses in agreement or 
strong agreement. Statements 8, 9, 10 and 16 had the most favorable responses (M = 4.6, SD = 
0.55), indicating strong agreement in the area of attitude to change and client benefit from the 
addition of services. Responses to Statement 7 and Statement 8 pertained to leadership and 
management in the change process, with responses ranging from neutral to strongly agree (M = 
3.8, SD = 0.84; M = 4.6, SD = 0.55, respectively). The lowest rated responses occurred in 
Statement 11 through Statement 15; these statements related to areas for communication and 
preparation for change, which averaged between neutral and agree (3.0 – 3.3). Statement 13 had 
the least agreement (M = 3.0, SD = 0.71), representing a neutral response to the statement, “I am 
adequately trained to offer contraceptive services within my role and scope of practice.” One 
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additional comment was provided from a respondent, stating, “Communication between staff can 
be improved.” 
LARC Training Evaluation 
Four attendees completed the LARC training evaluation following the second training 
session. One of the providers attended both trainings. All providers rated training satisfaction as 
very satisfied regarding overall training quality, quality of instruction, training materials, and the 
training experience. Providers rated strong agreement with all statements regarding training 
organization, job applicability, instructor knowledge and preparedness, benefit and utilization of 
training, and appropriate training length.  One additional comment stated, “Great experience”.
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Section V: Discussion 
Summary 
The aim of this project was to design and prepare for a pilot project for initiation of 
contraceptive services at an addiction treatment center, with a larger goal of reducing rates of 
unintended pregnancy. Advanced practice providers (APP) in the community recovery setting are 
provided a prime opportunity to address reproductive health needs, to assess current barriers to 
effective contraceptive use, and to integrate contraceptive services within substance use 
treatment. The APP can identify any potential knowledge gaps and provide appropriate education 
regarding the available methods of birth control and their respective efficacies. Further, offering 
contraceptive services is within the scope of APP practice. 
In preparation for anticipated service expansion, data were collected from current clients, 
healthcare providers, and medical staff for future pilot rollout of contraceptive services at the 
addiction treatment center. Key findings included feedback from current clients demonstrating 
the need and interest in contraceptive services, as well as the lack of prior comprehensive 
contraceptive counseling in the past. The most common client concerns cited regarding birth 
control methods were related to side effects and hormones. Regarding the healthcare providers 
readiness to offer contraception, respondents indicated they felt more prepared and confident to 
engage in contraceptive counseling that includes LARC safety and efficacy and more confident 
to perform IUD and Nexplanon insertion and removal procedures. Lastly, the medical staff 
indicated largely positive responses in terms of need for change, attitude for change, and 
leadership and management’s role in the change process. However, the mean response was 
neutral, not in disagreement nor agreement, with being prepared to offer such services within 
their scope of practice. 
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Interpretation 
The expected outcomes of this project included an improvement in provider confidence 
and readiness with contraceptive counseling and LARC procedures following the training 
intervention. Research has shown that following additional training, providers have demonstrated 
increased efficacy-based contraceptive counseling that includes LARC methods (Birgisson et al., 
2015; Gibbs et al., 2016; Harper et al., 2015). Findings of this LARC training intervention were 
consistent with previous research results.  
Results from the client survey in the women’s focus group showed a great interest and 
demand in the possibility of receiving contraceptive services within the substance use treatment 
program. Ninety percent of the women who completed surveys reported they would like to 
receive expanded services to include birth control services and STI testing, indicating 
consequences of unprotected sex is a concern. This number was higher than expected and 
perhaps represented the impact of the contraceptive counseling provided by this DNP student 
within the focus group. Approximately 50% of respondents reported interest in receiving the 
non-hormonal Cu-IUD, which was consistent with their most commonly reported concerns about 
side effects and hormones. 
Additional outcomes included the completion of the feasibility analysis, with subsequent 
presentation to site board members. Based on the overall responses from the medical staff, there 
was confirmed interest in expanding services to include contraceptive services. The results from 
the staff readiness for change survey were largely favorable, but indicated areas for improvement 
within the organization, such as staff communication and further instruction on role development 
prior to future pilot rollout. Prior to pilot initiation, this DNP student can identify additional 
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training resources to prepare the ancillary medical staff with role-specific information and 
communication tools.  
Limitations 
Limitations form the project intervention include the inability for providers who 
completed the training to immediately offer contraceptive services. With a delay from training to 
insertion-related procedures, provider confidence and readiness may regress. However, practice 
tools for insertion were obtained from the IUD representatives to keep on site to refresh skills for 
insertion and were given to each participant at the Nexplanon training. The product 
representatives also provided pocket instruction tools to review the sequence of procedural steps 
for IUD insertion. In addition, this DNP student created LARC training resource folders with 
hard copies of all information covered during the trainings.  
The main barrier to implementation of a future pilot project is the current inability to bill 
for reimbursement of medical services at the project site. In order to overcome this barrier, 
regular meetings were held with the medical services coordinator and practice manager to 
monitor the medical reimbursement status. However, external funding resources, including grant 
opportunities, were recognized as a potential way to overcome this barrier. Two grant 
opportunities were identified by this DNP student in preparation for future pilot initiation, but 
were not currently accepting applications. Future monitoring of an open application cycle will be 
necessary to further explore grant funding. Other limitations include time availability to offer 
same-day contraceptive services. While there are three providers employed by the clinic, they 
have alternating schedules. Priority is placed on detox, follow-up visits, and medication-assisted 
treatment patients. Identifying a routine time and or day of availability to offer LARC specific 
services might be ideal to reduce the competing demands. 
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Conclusions 
Unintended pregnancy is a significant problem in women with SUD, with economic and 
health consequences. Both LARC methods have demonstrated safety and efficacy among various 
groups of women, including adolescents, nulliparous women, and those at high risk for STI 
(Foran et al., 2018; Jatlaoui, Simmons, & Curtis, 2016; Jatlaoui, Riley, & Curtis, 2017). Rates of 
unintended pregnancy can be greatly reduced through LARC utilization, which is considered the 
most effective reversible category of birth control other than abstinence. Methods for increased 
LARC uptake include efficacy-based contraceptive counseling and provider training (Birgisson 
et al., 2015; Gibbs et al., 2016; Harper et al., 2015).  
Providing contraceptive services with an integrated approach, coinciding with substance 
use treatment, addresses barriers to access. Fragmented care and requiring multiple visits to 
receive LARC methods are known critical barriers to use (Higgins et al., 2018). Therefore, same-
day contraceptive services further increase the likelihood of use, while reducing the likelihood of 
unintended pregnancy. Ultimately, routine offering of contraceptive services in substance use 
treatment is ideal to mitigate barriers in women with SUD. Implications for future practice are 
not limited to substance use treatment alone. Any healthcare practice with limited contraceptive 
services may benefit from additional provider training to further reduce barriers to access of 
contraception. 
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Section VI: Other Funding 
Funding 
There were no outside funding sources provided for this quality improvement project. 
There are no conflicts of interest to disclose. The product representatives offered their time 
training at no cost.  
 
 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  48 
 
Section VII: References 
Agency for Healthcare Research and Quality. (2013). Clinical-community relationships 
evaluation roadmap. Retrieved from 
https://www.ashrq.gov/prevention/resources/chronic-care/clinical-community-
relationships-eval-roadmap/index.html 
American Academy of Pediatrics. (2014). Contraception for adolescents (Policy Statement). 
Retrieved from 
http://pediatrics.aappublications.org/content/pediatrics/134/4/e1244.full.pdf 
American College of Obstetricians and Gynecologists. (2017). Practice bulletin number 186: 
Long-acting reversible contraception: Implants and intrauterine devices. Obstetrics and 
Gynecology, 130(5), e251-e269. doi:10.1097/AOG.0000000000002400 
Birgisson, N. E., Zhao, Q., Secura, G. M., Madden, T., & Peipert, J. F. (2015). Preventing 
unintended pregnancy: The contraceptive CHOICE project in review. Journal of 
Women's Health, 24(5), 349-353. doi:10.1089/jwh.2015.5191 
Black, K. I., & Day, C. A. (2016). Improving access to long-acting contraceptive methods and 
reducing unplanned pregnancy among women with substance use disorders. Substance 
Abuse: Research & Treatment, 10(1), 27-33. doi:10.4137/SART.S34555 
Centers for Disease Control and Prevention. (2014). Providing quality family planning services: 
Recommendations of CDC and the U.S. Office of Population Affairs. Morbidity and 
Mortality Weekly Report, 63(4). Retrieved from 
https://www.cdc.gov/mmwr/pdf/rr/rr6304.pdf 
 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  49 
 
Committee on Obstetric Practice & American Society of Addiction Medicine. (2017, August). 
ACOG committee opinion: Opioid use and opioid use disorder in pregnancy (No. 711). 
Retrieved from https://www.acog.org/Clinical-Guidance-and-Publications/Committee-
Opinions/Committee-on-Obstetric-Practice/Opioid-Use-and-Opioid-Use-Disorder-
inPregnancy?IsMobileSet=false  
Dang, D., & Dearholt, S. (2017). Johns Hopkins nursing evidence-based practice: Model and 
guidelines (3rd ed.). Indianapolis, IN: Sigma Theta Tau International. 
Department of Health Care Services. (2019). Medi-Cal rates. Retrieved from https://files.medi-
cal.ca.gov/pubsdoco/Rates/rates_download.asp 
Finer L. B., & Zolna, M. R. (2016). Declines in unintended pregnancy in the United States, 2008 
2011. New England Journal of Medicine, 374(9), 843-852. doi:10.1056/NEJMsa1506575 
Foran, T., Butcher, B. E., Kovacs, G., Bateson, D., & O’Connor, V. (2018). Safety of insertion of 
the copper IUD and LNG-IUS in nulliparous women: A systematic review. European 
Journal of Contraception & Reproductive Health Care, 23(5), 379-386. 
doi:10.1080/13625187.2018.1526898 
Foster, D. G., Biggs, M. A., Malvin, J., Bradsberry, M., Darney, P., & Brindis, C. D. (2013). 
Cost-savings from the provision of specific contraceptive methods in 2009. Women’s 
Health Issues, 23(4), e265-e271. doi:10.1016/j.whi.2013.05.004 
Gibbs, S. E., Rocca, C. H., Bednarek, P., Thompson, K. M. J., Darney, P. D., & Harper, C. C. 
(2016). Long-acting reversible contraception counseling and use for older adolescents 
and nulliparous women. Journal of Adolescent Health, 59(6), 703-709. 
doi:10.1016/j.jadohealth.2016.07.018 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  50 
 
Granite Wellness Centers. (2019). Our mission. Retrieved from 
https://www.granitewellness.org/our-mission/ 
Grunloh, D. S., Casner, T., Secura, G. M., Peipert, J. F., & Madden, T. (2013). Characteristics 
associated with discontinuation of long-acting reversible contraception within the first 6 
months of use. Obstetrics & Gynecology, 122(6), 1214-1221. 
doi:10.1097/01.AOG.0000435452.86108.59 
Harper, C. C., Rocca, C. H., Thompson, K. M., Morfesis, J., Goodman, S., Darney, P. D., …  
Speidel, J. J. (2015). Reductions in pregnancy rates in the USA with long-acting 
reversible contraception: A cluster randomised trial. Lancet, 386 North American Edition, 
386(9993), 562-568. doi:10.1016/S0140-6736(14)62460-0 
Heil, S. H., Jones, H. E., Arria, A., Kaltenbach, K., Coyle, M., Fischer, G., … Martin, P. R. 
(2011). Unintended pregnancy in opioid-abusing women. Journal of Substance Abuse 
Treatment, 40(2), 199-202. doi:10.1016/j.jsat.2010.08.011 
Higgins, T. M., Dougherty, A. K., Badger, G. J., & Heil, S. H. (2018). Comparing long-acting 
reversible contraception insertion rates in women with Medicaid vs. private insurance in 
a clinic with a two-visit protocol. Contraception, 97(1), 76-78. 
doi:10.1016/j.contraception.2017.08.016 
Jatlaoui, T. C., Riley, H. E. M., & Curtis, K. M. (2017). The safety of intrauterine devices among 
young women: A systematic review. Contraception, 95(1), 17-39. 
doi:10.1016/j.contraception.2016.10.006  
 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  51 
 
Jatlaoui, T. C., Simmons, K. B., & Curtis, K. M. (2016). The safety of intrauterine contraception 
initiation among women with current asymptomatic cervical infections or at increased 
risk of sexually transmitted infections. Contraception, 94(6), 701-712. 
doi:10.1016/j.contraception.2016.05.013 
Luchowski, A. T., Anderson, B. L., Power, M. L., Reglan, G. B., Espey, E., & Schulkin, J. 
(2014). Obstetrician-gynecologists and contraception: Long-acting reversible 
contraception practices and education. Contraception, 89(6), 578-583. 
doi:10.1016/j.contraception.2014.02.004 
Matusiewicz, A. K., Melbostad, H. S., & Heil, S. H. (2017). Knowledge of and concerns about 
long-acting reversible contraception among women in medication-assisted treatment for 
opioid use disorder. Contraception, 96(5), 365-369. 
doi:10.1016/j.contraception.2017.07.167 
Modesto, W., Bahamondes, M. V., & Bahomondes, L. (2014). A randomized clinical trial of the 
effect of intensive versus non-intensive counseling on discontinuation rates due to 
bleeding disturbances of three long-acting reversible contraceptives. Journal of Human 
Reproduction, 29(7), 1393-1399. doi:10.1093/humrep/deu089 
National Center for Health Statistics. (2017). National survey on drug use and health: Trend 
tables. Retrieved from https://www.cdc.gov/nchs/data/hus/2017/050.pdf 
National Center for Health Statistics. (2019). National survey of family growth. Retrieved from 
https://www.cdc.gov/nchs/nsfg/key_statistics/L.htm#larc 
National Center for Youth Law. (2003, January). California minor consent laws. Retrieved from 
https://www.csus.edu/indiv/b/brocks/courses/eds%20245/handouts/week%207/ca_minor
_consent.pdf 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  52 
 
National Institute for Health and Care Excellence. (2019). Long-acting reversible contraception 
(NICE Clinical Guideline No. 30) Retrieved from 
https://www.nice.org.uk/guidance/cg30/chapter/1-Recommendations 
National Institute on Drug Abuse. (2015). Nationwide trends. Retrieved from 
https://www.drugabuse.gov/publications/drugfacts/nationwide-trends 
National Institute on Drug Abuse. (2019). Opioid overdose crisis. Retrieved from 
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis 
Nevada County Public Health Department. (2016). Nevada county community health assessment. 
Retrieved from 
https://www.mynevadacounty.com/DocumentCenter/View/13812/Nevada-County-
Community-Health-Assessment-PDF?bidId= 
Office of Disease Prevention and Health Promotion. (2014). Healthy people 2020: Family 
planning. Retrieved from https://www.healthypeople.gov/2020/topics-
objectives/topic/family-planning?topicid=13 
Office of Population Affairs. (2019). Intrauterine device. Retrieved from 
https://www.hhs.gov/opa/pregnancy-prevention/birth-control-methods/iud/index.html 
Raifman, S., Barar, R., & Foster, D. (2018). Effect of knowledge of self-removability of 
intrauterine contraceptives on uptake, continuation, and satisfaction. Women’s Health 
Issues, 28(1), 68-74. doi:10.1016/j.whi.2017.07.006 
Reproductive Health Access Project. (n.d.). Getting started with LARC. Retrieved from 
https://www.reproductiveaccess.org/programs/hartcenter/getting-started/ 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  53 
 
Robert Wood Johnson Foundation. (2015). County health rankings & roadmaps: Nevada county, 
California. Retrieved from 
http://www.countyhealthrankings.org/app/california/2014/rankings/nevada/county/outco
mes/ overall/snapshot 
Shasta County Health and Human Services Agency. (2018). The health of rural and urban 
California counties. Retrieved from https://www.co.shasta.ca.us/docs/libraries/hhsa-
docs/community-health-data/rural-vs-urban-report-2018.pdf?sfvrsn=988bfa89_0 
Sonfield, A., & Kost, K. (2015). Public costs from unintended pregnancies and the role of public 
insurance programs in paying for pregnancy-related care: National and state estimates 
for 2010. New York, NY: Guttmacher Institute. 
Terplan, M., Hand, D. J., Hutchinson, M., Salisbury-Afshar, E., & Heil, S. H. (2015). 
Contraceptive use and method choice among women with opioid and other substance use 
disorders: A systematic review. Preventive Medicine, 80, 23-31. 
doi:10.1016/j.ypmed.2015.04.008 
Terplan, M., Lawental, M., Connah, M. B., & Martin, C. E. (2016). Reproductive health needs 
among substance use disorder treatment clients. Journal of Addiction Medicine, 10(1), 
20-25. doi:10.1097/ADM.0000000000000175 
University of California San Francisco, Bixby Center for Global Reproductive Health. (n.d.). 
LARC insertion and removal materials checklists. Retrieved from 
https://larcprogram.ucsf.edu/sites/larcprogram.ucsf.edu/files/Materials_for_Insertion_Re
moval.pdf 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  54 
 
University of California San Francisco, Bixby Center for Global Reproductive Health. (2015). 
Intrauterine devices & implants: A guide to reimbursement. Retrieved from 
https://larcprogram.ucsf.edu/obtaining-supplies 
World Health Organization. (2019). Substance abuse. Retrieved from 
https://www.who.int/topics/substance_abuse/en/ 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  55 
 
Section VIII: Appendices 
 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  56 
 
Appendix A. Evaluation Table 
Citation 
Design/Method Sample/Setting 
Major Variables 
Defined 
Data Analysis Study Findings Limitations 
Birgisson et al. 
(2015)  
Observational 
cohort study 
 
Examined the 
effect of tiered 
contraceptive 
counseling on 
LARC uptake and 
continuation (with 
removal of 
barriers to access, 
cost and 
education).  
9,000 women 
aged 14-45 years 
recruited through 
convenience 
sampling 
 
St. Louis region 
Intervention: 
Tiered 
contraceptive 
counseling 
provided by 
trained counselors 
based on efficacy 
 
Contraceptive 
choice provided at 
no cost for 2-3 
years 
 
Outcomes: 
Contraceptive 
method choice and 
continuation 
Descriptive 
analysis with 
summary statistics  
75% chose a LARC method. 
 
Higher continuation among 
LARC users compared with 
non-LARC users at 12 
months (87% vs. 57%) and 
24 months (77% vs 41%). 
 
 
Variability among 
individual 
counselors 
 
No comparison 
group  
 
Services were 
provided at 
different sites and 
clinics 
 
Contraception was 
provided at no 
cost  
 
Generalizability 
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Harper et al. 
(2015)  
Cluster-
randomized trial 
 
Examined the 
effect of 
clinic/clinician 
contraceptive and 
insertion training 
on patient LARC 
selection.  
40 Planned 
Parenthood clinics 
in the USA 
 
Eligible women 
were 18-25 years 
old 
 
2-month 
recruitment 
process with paid 
incentives for 
participation 
 
Intervention: 
Clinic training to 
improve 
providers’ 
method-specific 
knowledge and 
counseling and 
placement skills 
 
Outcomes: LARC 
selection and 
pregnancy rates 
Analyses through 
intention to treat 
 
Logistic 
regression to 
estimate 
intervention effect 
on LARC uptake 
 
Life-table analysis 
and Kaplan-Meier 
survival estimates 
on pregnancy rates 
 
 
Women were more likely to 
choose a LARC in the 
intervention group, 
intracluster correlation 0.05 
(95 CI, 0.02 to 0.08). 
 
Increase in the proportion of 
women using LARCs in the 
intervention compared to 
control group (2.3% vs 2.0%, 
coefficient for difference 
0.0004, 95% CI 0.003-
0.004). 
 
Pregnancy rates were 15 per 
100-perosn years in 
intervention group vs. 18.5 
per 100 person-years in the 
control (hazard ratio 0.89, 
95% CI 0.64-1.24). 
 
Outside funding 
source 
 
Variability among 
providers and 
clinics 
 
Generalizability to 
clinics outside of 
Planned 
Parenthood 
 
Un-blinded upon 
assignment of 
intervention 
 
Additional patient 
education tools 
provided 
 
Modesto et al. 
(2014)  
 
 
Randomized-
clinical trial 2011 
to 2013 
 
Brazil 
297 women that 
selected either a 
98 ENG-implant, 
99 LNG-IUS, or 
100 TCu380A 
IUD 
 
 
Intervention: 
Intensive 
counseling at 45 
days, 6 months, 
and 12 months 
following 
insertion 
 
Comparison: 
Routine 
counseling 
 
 
Outcomes: 
Continuation 
rates, reasons for 
discontinuation, 
user satisfaction at 
12 months 
SPSS version 20 
 
ANOVA or 
Kruskal-Wallis 
test 
 
Chi-squared test 
Discontinuation rates due to 
expulsion were higher for the 
Cu-IUD (p = 0.008), due to 
weigth gain among ENG-
implant (p = 0.022). 
 
There were no significant 
differences of women 
discontinuing the method due 
to bleeding in either group. 
 
1-year continuation rate was 
73% for Cu-IUD, 83% ENG-
implant. 
 
User satisfaction was 86% 
for the Cu-IUD and 90% for 
the LNG-IUS. 
Standard 
counseling 
potentially already 
adequate 
 
Possible patient 
information 
sharing in waiting 
room 
 
External funding 
source 
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Raifman et al. 
(2018)   
Prospective cohort 
study  
 
Evaluated the 
effect on 
counseling 
containing IUD 
self-removal on 
uptake, 
satisfaction, and 
continuation. 
 
361 women who 
selected IUD after 
contraceptive 
counseling   
 
Family planning 
clinics in 
Michigan, 
Missouri, New 
Jersey, and Utah 
  
 
 
Intervention: 
Counseling, 
including IUD 
self-removal 
 
Outcomes: IUD 
uptake, 
satisfaction, and 
continuation 
Descriptive 
analyses on effect 
of study group on 
adoption of the 
method, method 
satisfaction, 
continuation, 
reasons for 
discontinuation 
 
Multivariable 
discrete-time 
logistic survival 
model on 
relationship 
between study 
group and IUD 
discontinuation 
 
No significant difference in 
IUD uptake rate by group 
(control 7% [95% CI, 6.8-
7.8]; intervention 7% [95% 
ci, 6.4-7.5]). 
 
At the New Jersey site, 
uptake was higher among the 
intervention group (13% vs 
85; p = 0.006), but lower at 
another site (12% vs. 17%; p 
= 0.044). 
 
There were no differences in 
continuation rates by group 
or state. 
 
Control participants were 
more likely to consider 
discontinuation at 6 months 
(15% vs 7%: p = 0.047) 
Pre-existing 
knowledge 
regarding self-
removal 
 
Confounders 
related to time 
differences in 
recruitment for 
control and 
intervention group 
 
Small sample size 
 
Variation in sites 
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Gibbs et al. 
(2016)   
Cluster 
randomized trial 
 
Examined the 
effect of provider 
LARC training on 
LARC use. 
1,500 sexually 
active women 
aged 18-25 
 
20 intervention 
and 20 control 
clinics 
 
Random 
allocation to 
intervention to 
control groups 
Intervention: 
Provider LARC 
training 
 
Outcomes: LARC 
counseling, LARC 
selection, LARC 
initiation 
Stata version 14.0  
 
Logistic 
regression 
 
Cox proportional 
hazards model 
  
 
Young adults and 
adolescents in the 
intervention group were 
more likely to select a LARC 
than the control (73% vs 
41%, 66% vs 33%, 
respectively). 
 
Initiation rates were higher 
among the intervention 
group.  
 
Nulliparous women 
compared with parous 
women had lower rates of 
LARC counseling (.57; 95% 
CI: .42 - .79), lower LARC 
selection (adjusted Odds 
Ratio = .53; 95% CI: .37 - 
.75), and lower LARC 
initiation (adjusted Hazards 
Ratio = .65; 95% CI: .48-
.90). 
Participants aged 
18-25 years only 
 
Outside funding 
source 
 
Generalizability 
 
Variability among 
providers and 
clinics 
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Appendix B. Gap Analysis 
 
Gap Analysis 
Project 
Name 
LARC Method Appropriateness in Substance Use Treatment:  
A Quality Improvement Project for Integrated Care 
Date May 2019 
Project 
Aim 
The predominant aim of this quality improvement project is to reduce rates of unintended pregnancy 
among women with SUD through the development of a pilot project that integrates evidence-based 
contraceptive services, emphasizing highly effective methods. 
Current State Best Practice Proposed Solution  
Unintended pregnancy rates are 
estimated to be 85% among women 
with a substance use disorder. 
Recommend offering a LARC 
option, including: 
• Same-day service when 
possible  
• Without delaying for the 
results of STI testing with 
normal examine findings and 
reasonable certainty that 
client is not pregnant 
A feasibility analysis will be 
conducted to design and develop a 
pilot project rollout of the 
incorporation of LARC services 
within substance use treatment 
appointments. 
Client misperceptions regarding 
LARC methods and limited 
knowledge regarding side effects, 
efficacy, and potential adverse 
effects. 
Recommend comprehensive 
contraceptive counseling including: 
• Efficacy rates 
• Side effects 
• Potential adverse outcomes 
• Respect of patient autonomy 
 
Providers will be delivered a 
LARC-focused training that 
includes evidence-based 
recommendations regarding 
contraceptive counseling and 
hands-on skills training. 
Contraceptive use screening in 
medical appointments for clients 
receiving inpatient and outpatient 
substance use treatment. 
Recommend the integration of 
contraceptive services within 
substance use treatment. 
Identify 2 possible funding sources, 
including grant opportunities, for 
the expansion of contraceptive 
services. 
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Appendix C. Letter of Support 
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Appendix D. GANTT Chart 
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Appendix E. Work Breakdown Structure 
1.0 Design 
1.1 Develop Project Scope 
1.2 Needs Assessment/Gap Analysis 
1.3 Develop Objectives 
1.4 Identify Key Stakeholders 
1.5 Develop Project Charter 
1.6 Submit Project Charter 
2.0 Plan 
2.1 Identify Project Team 
2.2 Discussion of Roles 
2.3 Develop Project Plan 
2.4 Develop WBS 
2.5 Develop Surveys 
2.6 Prepare Staff Training Protocol 
3.0 Intervention 
3.1 Feasibility Analysis 
3.1.1 Women’s Focus Group 
3.1.2 Staff Survey 
3.1.3 Site Survey 
3.2 Develop Policies and Procedures 
3.3 LARC Training Workshop 
3.3.1 LARC Training 1 
3.3.1.1 Bayer Skills Training: Mirena, Skyla, Kyleena 
3.3.1.2 Best Practice Review 
3.3.2 LARC Training 2 
3.3.2.1 CooperSurgical Skills Training: ParaGard 
3.3.2.2 Nexplanon Training & Certification 
3.4 Identify Funding Sources 
4.0 Results 
4.1 Present Results to the Board Committee 
4.1.1 Analyze Survey Findings 
4.1.2 Summarize Findings and Write Recommendations 
5.0 Evaluation 
5.1 Identify Student for Pilot Hand-Off 
5.2 Review Training Feedback 
5.3 Write Final Report 
5.4 Dissemination 
5.4.1 DNP Paper 
5.4.2 DNP Presentation 
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Appendix F. Communication Matrix 
 
Activity Purpose Responsible 
Person 
Involved 
Stakeholders 
Disseminate 
Project to Staff 
Engage staff 
member 
involvement and 
obtain buy-in 
Project Leader Medical staff 
Project Proposal  Gain approval 
for project 
implementation 
Project Leader Board members 
and medical 
director 
Staff Meetings Project updates, 
revisions, 
training, and 
evaluation 
Project Leader 
Project Chair 
All project 
members 
including 
clinical site 
participating 
staff 
Feasibility Study To gather data 
from appropriate 
stakeholders  
Project Leader 
 
Providers on 
site, medical 
staff, and current 
clients 
Program 
Evaluation 
Analysis and 
dissemination of 
results 
All Project Team 
Members 
Board members 
and clinical staff 
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Appendix G. SWOT Analysis 
Strengths 
• Promoting patient involvement in care 
• Increasing access to community-based 
resources 
• Providing access to care  
• Providing contraceptive services  
• Providing patient education regarding 
contraceptive methods 
• Educating regarding common myths  
• Pre-existing on-site medical clinic 
• Two patient exam rooms 
• Three experience healthcare providers on staff 
• Regular staff process improvement meeting  
 
 
Weaknesses 
• Cost  
• Inability to bill for reimbursement 
• Substance use appointments will take priority 
• Limited time available  
• Limited providers available 
• Patient misbeliefs and misperceptions 
Opportunities 
• To reduce rates of and prevent unintended 
pregnancy 
• Reduce potential adverse maternal and fetal 
outcomes associated with unplanned 
pregnancy 
• Provide comprehensive, evidence-based 
contraceptive counseling 
• Increase client satisfaction in contraceptive 
method choice and increase greater control 
over family planning 
• To perform STI screening  
• To perform pregnancy screening 
• Extend contraceptive services to additional 
campuses within the organization 
 
 
 
 
Threats 
• Clinic closure 
• Competing reproductive service sites  
• Patient attrition 
• Repeal of the Affordable Care Act 
• Lack of external funding source 
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Appendix H. Cost-Benefit Analysis 
 
Costs Pilot Study Cost 
(Initial 3 
Months) 
FY1 FY2 
Fixed Asset Start-Up Expenses     
Medical Equipment  $299.00 $0 $0 
Furniture $1,395.00 $0 $0 
Total Fixed Asset Start-Up Expenses $1,694.00 $0 $0 
Operating Expenses 
 
  
Salaries and Wages (0.05 NP FTE ) $3,799.80 $15,199.2 $15,487.96 
Benefits at 30% of Employee’s Salary  $1,139.94 $4,559.76 $4,646.40 
Medical Supplies $10,133.40 $40,533.60 $40,533.60 
Contracted Services $825.00 $3,300.00 $3,300.00 
Miscellaneous Costs (Support staff, 
Forms, etc.) 
$105 $420 $420 
Total Operating Expenses $16,003.14 $64,012.56 $64,387.96 
Total Costs $17,697.14 $65,706.56 $64,387.96 
Revenue    
Projected billable revenue through 
Medi-Cal Reimbursement for 
contraceptive counseling, IUD, IUD 
Insertion, Dispensing Fee, Follow-up 
Visit, STI Testing)  
$17,490.90  $69,963.60 $69,963.60 
Total Gross Revenue $17,490.90 $69,963.60 $69,963.60 
Net Revenue  ($206.24) $4,257.04 $5,575.64 
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Appendix I. IUD Policy and Procedure 
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Appendix J. Patient Education Materials 
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Appendix K. Site Assessment 
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Appendix L. Patient Satisfaction Survey 
 
Patient Satisfaction Survey  
Thank you for taking the time to complete this survey. Your feedback will be used to improve 
the services offered.  
s Strongly 
Agree 
Agree Neutral Disagree Strongly 
Disagree 
Not 
Applicable 
Receiving contraceptive services 
and counseling was helpful. 
      
Contraceptive counseling was 
provided by the healthcare 
provider that helped me make an 
informed decision. 
      
I was provided instructions 
regarding method choice and 
follow-up care. 
      
The provider gave me his or her 
attention. 
      
The provider understood and 
addressed my concerns. 
      
The provider answered my 
questions clearly. 
      
I am satisfied with my visit. 
      
I am satisfied with the quality of 
care I received. 
      
It was easy to schedule a follow-
up appointment.  
      
I received the results of my lab 
tests in a timely manner.  
      
I did not have difficulty obtaining 
a contraception method of my 
choosing. 
      
I would recommend the services 
I received to other patients. 
      
 
What can we do differently in the future to make your experience more positive? 
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Appendix M. Women’s Focus Group Survey 
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Appendix N. Staff Readiness for Change Survey 
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Appendix O. LARC Training Workshop Presentation 
 
 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  80 
 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  81 
 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  82 
 
 
LARC APPROPRIATENESS IN SUBSTANCE USE TREATMENT  83 
 
Appendix P. LARC Training Folder Resources 
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Appendix Q. LARC Workshop Pre- and Post-Engagement Surveys 
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Appendix R. LARC Training Evaluation 
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Appendix S. DNP Statement of Non-Research Determination Form 
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Appendix T. Client Survey Results 
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Appendix U. Pre-Post LARC Training 1 Intervention Results 
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Appendix V. Pre-Post LARC Training 2 Intervention Results 
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 Appendix W. Staff Readiness for Change Survey Results 
 
 
